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Abstract
Background—Depression affects 18-30% of HIV-infected patients in Africa and is associated
with greater stigma, lower antiretroviral adherence, and faster disease progression. However, the
region's health system capacity to effectively identify and treat depression is limited. Task-shifting
models may help address this large mental health treatment gap.
Methods—Measurement-Based Care (MBC) is a task-shifting model in which a Depression Care
Manager (DCM) guides a non-psychiatric (e.g., HIV) provider in prescribing and managing
antidepressant treatment. We adapted MBC for depressed HIV-infected patients in Cameroon and
completed a pilot study to assess feasibility, safety, acceptability, and preliminary efficacy.
Results—We enrolled 55 participants; all started amitriptyline 25-50mg daily at baseline. By 12
weeks, most remained at 50mg daily (range 25-125mg). Median (interquartile range) PHQ-9
depressive severity scores declined from 13 (12-16) (baseline) to 2 (0-3) (week 12); 87% achieved
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depression remission (PHQ9<5) by 12 weeks. Intervention fidelity was high: HIV providers
followed MBC recommendations at 96% of encounters. Most divergences reflected a failure to
increase dose when indicated. No serious and few bothersome side effects were reported. Most
suicidality (prevalence: 62% at baseline; 8% at 12 weeks) was either passive or low-risk.
Participant satisfaction was high (100%), and most participants (89%) indicated willingness to pay
for medications if MBC were implemented in routine care.
Conclusions—The adapted MBC intervention demonstrated high feasibility, safety,
acceptability, and preliminary efficacy in this uncontrolled pilot study. Further research should
assess whether MBC could improve adherence and HIV outcomes in this setting.
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Introduction
Depression is a common comorbidity among HIV-infected individuals in sub-Saharan
Africa, with important implications for the success of HIV medical care. Depression affects
an estimated 18-30% of patients receiving HIV care in Africa.(1) Among HIV-infected
patients in Africa, depression is associated with greater perceived stigma, lower
antiretroviral medication adherence, tuberculosis comorbidity, and more advanced disease
stage.(1-3) This growing literature among African populations is consistent with a much
deeper literature delineating the high prevalence and negative clinical consequences of
depression for HIV-infected individuals in high-income countries.(2, 4-7)
Despite the high prevalence and negative consequences of depression, the capacity of health
systems in much of sub-Saharan Africa to effectively treat depressive disorders is virtually
nonexistent.(8) The World Health Organization's Mental Health Gap Action Programme
(mhGAP) estimates that in low-income countries, 75% of those needing mental health
treatment do not have access to any such treatment.(8) Among Sub-Saharan African nations,
the median number of mental health professionals is 1.7 per 100,000 population,(9) less than
one-fiftieth the rate in the United States (92.7 mental health professionals per 100,000
population).(10) This shortfall in mental health treatment affects not only the general
population but also HIV-infected individuals, with related consequences for the success of
their HIV clinical care.
In the face of this dearth of skilled mental health professionals, the primary hope for
addressing the large burden of mental health needs in low-income countries lies in task-
shifting models that focus on training non-specialists, such as primary care providers and
community workers, to address common mental health problems.(8) These models generally
emphasize supervision of non-specialists by more skilled professionals, with a stepped-care
approach that permits the majority of patients to be managed effectively by the non-
specialists while complex cases are referred for more specialized treatment.
One such model, Measurement-Based Care (MBC), has a large evidence base from studies
with primary care patients in the United States.(11) The Sequenced Treatment Alternatives
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to Relieve Depression (STAR*D) trial, the largest trial of depression treatment to date,
demonstrated that with MBC, primary care settings can deliver depression treatment
equivalent to that provided in specialty psychiatric clinics.(11) MBC was recently adapted
for use with HIV-infected patients in the US,(12) with particular attention paid to
antiretroviralantidepressant interactions. However, the model has not previously been used
in settings with the extremely sparse mental health infrastructure that characterizes much of
sub-Saharan Africa. We adapted MBC for implementation with HIV-infected patients with
depression in Bamenda, Cameroon, and completed a prospective pilot study to assess the




Measurement-Based Care (MBC) is an evidence-based, resource-efficient depression
management strategy which equips non-psychiatric medical providers to deliver best-
practices medication management for depression.(12) Consistent with principles of task-
shifting and chronic disease management successfully applied to a range of chronic
illnesses, MBC relies on a non-physician Depression Care Manager (DCM) to regularly
assess key metrics of depression treatment. The DCM then provides decision support to the
treating (non-psychiatric) provider regarding antidepressant initiation, dosing, and
switching. With appropriate supervision, the role of the DCM may be effectively filled by
individuals with a range of training, including nurses or social workers.
In the general MBC timeline, a patient initiates an antidepressant after confirmation of
current major depression and ruling-out of a bipolar or psychotic disorder (Figure 1).
Critical Decision Points (CDPs) for treatment adjustment occur every 4 weeks. At each
CDP, the patient rates his or her depressive severity and the intensity and tolerability of any
side effects using standardized measures. These metrics guide a recommendation to
increase, maintain, or decrease the antidepressant dose or to change treatments (Figure 2). In
general, if the patient is tolerating the medication but the depressive severity assessment
indicates that remission (full resolution of symptoms) has not been achieved, a dose increase
will be recommended and then re-evaluated at the next CDP. At CDP3 (i.e., after 12 weeks
and up to 2 dose increases), the patient is determined either to have achieved remission (in
which case she enters a maintenance phase of reduced contact frequency) or to have
demonstrated treatment resistance to the current medication (in which case a new treatment
plan is recommended). Additional interim contacts occur between CDPs, at weeks 2, 6, and
10, to monitor tolerability and address side effects if needed.
Adaptation of MBC
As part of an NIMH-funded grant (“Adaptation of a Depression Treatment Intervention for
HIV Patients in Cameroon,” R34 MH084673, 2009-2012),(13) we adapted MBC for use in
Cameroon. The adaptation process consisted of the following steps: (1) focus group
discussions to adapt the language of a depression screening instrument (the PHQ-9)
(previously described);(14) (2) a validation study to determine the test characteristics of the
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PHQ-9 among HIV-infected patients in Cameroon (previously described);(14) (3) key
informant interviews with a variety of health care providers to define the existing (pre-
intervention) standard of care for patients presenting with mental health disorders; (4)
adaptation of medication and dosing recommendations in consultation with local medical
professionals to account for the antidepressants available; and (5) adaptation of staffing,
supervision, and referral pathway plans to the local context in consultation with local
medical professionals.
Pilot study procedures
This adaptation was followed by a pilot study to assess feasibility, acceptability, safety, and
preliminary efficacy of the adapted MBC intervention. The role of Depression Care
Manager was filled by a local individual with a nursing certificate (standard training for
nurses) with 12 years of experience as a pharmacy attendant and nurse at the Bamenda
Regional Hospital but without prior mental health training. Pre-launch training by study
investigators focused on diagnosis of depression and excluding diagnoses, approaches to
depression treatment with an emphasis on Measurement-Based Care, and management of
suicidality and medication side effects.
After training, recruitment for the pilot study occurred from April 15-November 30, 2011.,
HIV-infected patients presenting for care at the Bamenda Day Hospital AIDS Treatment
Center were routinely screened for depression using the PHQ-9 and invited to participate in
the study if they met the following eligibility criteria: (1) PHQ-9 score ≥10; (2) current
major depressive disorder confirmed through clinical assessment by the treating HIV
physician; (3) 18-65 years; (4) currently prescribed combination antiretroviral therapy. To
simplify issues of translation and ensure consistency of measurement for this pilot study,
participants needed to be able to communicate effectively in English to participate. In the
English-speaking region of Camerron where this study was conducted, all medical care is
delivered in English and >90% of patients presenting for care at the Bamenda Day Hospital
AIDS Treatment Center can communicate effectively in English. Potential participants were
considered not eligible if they met any of the following exclusion criteria: (1) current acute,
high-risk suicidality or history of bipolar or psychotic disorder as determined through
clinical assessment by the treating HIV physician; (2) current substance abuse problem that
in the judgment of the clinician would need to be addressed prior to depression treatment.
Potentially eligible patients received information about all study activities, after which
interested individuals provided written informed consent.
At the time of enrollment, the Depression Care Manager provided a recommendation about
antidepressant prescription to the treating HIV physician. Consistent with the standard MBC
timeline,(12) the DCM had follow-up contact with each participant every 2 weeks through
week 12 post-enrollment (acute phase of treatment), with weeks 4, 8, and 12 representing
Critical Decision Points. Depressive symptom severity was measured with the PHQ-9,(15)
while side effects were evaluated with the Frequency, Intensity, and Burden of Side Effects
Rating Scale (FIBSER).(16) At the end of the acute phase (12 weeks), participants
completed a series of questions addressing their experiences with the MBC intervention.
After the acute phase, the DCM and participant had maintenance-phase contacts at months
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4, 8, and 12. Participants also completed research interviews with a separate interviewer (not
part of the clinical care team) and provided a blood sample for CD4 and HIV RNA viral
load measures at baseline and at months 4, 8, and 12. Participants received a small stipend at
each CDP to reimburse them for transportation, time, and clinic costs. All study medications
(first- and second-line) were provided free of charge for the duration of the study.
To ensure quality of care, the DCM had weekly supervision via teleconference with a
psychiatrist, the study PI [BNG], to review all visits and clinical decisions from the past
week. Supervision was guided by a simple participant tracking spreadsheet which
summarized key metrics for each participant visit: depressive severity, intensity of side
effects, suicidality, and treatment plan. A Data Safety and Monitoring Committee (DSMC)
reviewed study protocols and data annually.
Ethical approval
All study activities were approved by the Cameroon National Ethics Committee (No.
111/CNE/SE/09), the University of North Carolina at Chapel Hill's Biomedical Institutional
Review Board (IRB) (# 09-0852), and the Duke University Health System IRB (#
Pro00016937). The study also received administrative approval from the Ministry of Public
Health in Cameroon.
Measures
Feasibility was assessed by the ability to (1) identify appropriate and available
antidepressants, (2) identify and train an appropriate Depression Care Manager, (3) identify
and recruit eligible patients, (4) retain participants through a complete acute phase treatment
course, (5) monitor depressive symptoms and side effects and provide algorithm-concordant
recommendations to the treating HIV provider, (6) hold regular supervision to review
clinical indicators and decisions for quality assurance.
Fidelity was assessed by the congruency between the MBC recommendations (based on the
patient's depressive severity and medication tolerability) and the HIV provider's treatment
decision, recorded along with all other key clinical indicators in a tracking database that was
reviewed on a weekly basis with the supervising psychiatrist. Specific reasons for
divergence between the MBC recommendation and the HIV provider's treatment plan were
documented.
Safety was assessed by the occurrence of specific symptoms that could be signs of
anticholinergic toxicity (delirium or confusion, emerging mania, urinary tract infections,
urinary dysfunction, poor liver function, oral thrush, and insomnia), assessed both by
participant self-report and clinical exam, and by the frequency and severity of suicidal
ideation.
Acceptability was assessed by participant self-report of satisfaction with the intervention,
perceived physical and mental health benefit of the intervention, whether they would
recommend the intervention to others, whether the time cost of the intervention had been
acceptable, and whether the time and financial cost of the treatment approach would be
acceptable in the absence of a study.
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Preliminary efficacy was assessed by the proportion of participants achieving remission of
their depression (PHQ9 total score <5) at each time point.
Analysis Plan
Given the design of this pilot study, the results presented here are descriptive in nature.
Sample characteristics and measures of efficacy, safety, and acceptability are summarized
with medians and interquartile ranges (IQR) or frequencies and percentages. Fidelity is
described by classifying clinical decisions at each CDP as either congruent (following




The adaptation process yielded minor modifications to MBC. The most substantive
modification reflected the reality that the only readily available antidepressant in Cameroon
was amitriptyline (AMI), an older tricyclic antidepressant (TCA) which is primarily used at
lower doses to treat peripheral neuropathic pain. As part of the Cameroon National Essential
Drug List, AMI is nearly universally available at a heavily subsidized price. AMI has the
potential for sedation and anticholinergic side effects such as blurred vision, constipation,
urinary retention, and dry mouth, especially in HIV-infected individuals.(17-19) In treating
depression in high-income countries, TCAs have largely been replaced by selective
serotonin reuptake inhibitors (SSRIs) or other newer agents with more favorable side effect
profiles. The MBC approach already provides for gradual dose escalation with careful and
proactive side effect monitoring, an approach that was deemed appropriate by the DSMC for
monitoring AMI prescription and tolerability in this population.
A related modification involved the definition of second-line treatment options for
participants who did not tolerate or respond to AMI treatment. For this study, the identified
second-line options included referral to the region's psychiatric nurse, co-located at the
hospital, and fluoxetine, available at some local private pharmacies at a higher cost than
AMI.
A final modification related to safety monitoring. Particular attention was paid to monitoring
conditions that could be an early indication of problematic TCA toxicity in this HIV
population, including oral thrush, delirium, confusion, urinary tract infections, urinary
dysfunction, emerging mania, insomnia, and liver dysfunction. Additionally, participants
were strongly counseled to avoid all alcohol consumption, since alcohol would be expected
to inhibit the action of AMI and lead to greater sedation and increased risk of persistent
depressive symptoms.
Recruitment and retention
Between April 15 and November 30, 2011, 55 patients met eligibility criteria and enrolled.
The majority of participants (80%) were female (Table I). Participants ranged in age from
24-53 (median: 40). Participants had relatively strong CD4 counts (median: 454; IQR:
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242-612), but none had a suppressed viral load at baseline (median VL: 12,304 copies/mL;
IQR: 7,308-21,555). Baseline PHQ-9 depressive severity scores were in the moderate
(10-19) and severe (20-27) range for 87% and 13% of participants respectively. Only 4% of
participants reported that this was their first depressive episode; half indicated that they had
had at least three prior depressive episodes. Only one participant had ever received treatment
for depression.
Retention was high in both the clinical and research components of the study. One
participant died, for reasons not related to the study, after the week 4 visit and one
participant was withdrawn due to problematic alcohol consumption and liver toxicity
concerns after the week 8 visit. The 4-, 8-, and 12-week CDPs were completed by 100%
(55/55), 93% (50/54), and 100% (53/53) of remaining participants, respectively (Table II).
The 2-, 6-, and 10-week interim contacts (primarily for side effects monitoring) were
completed by 87% (48/55), 57% (31/54), and 34% (18/53) of participants. According to the
DCM, the lower retention at the interim contacts was primarily driven by transportation
barriers (while CDPs generally coincided with medication refill visits, interim contacts did
not) and low perceived need by participants not experiencing side effects. The research
interviews at months 4, 8, and 12 were completed by all remaining participants (53/53,
100%).
Intervention Implementation and Preliminary Efficacy
All participants were prescribed amitriptyline at their baseline visit at one of the two
recommended starting doses of 25mg daily (n=1) or 50mg daily (n=54) (Table II). At the
first CDP (week 4), all participants were tolerating the medication well and 35% of
participants had achieved remission of their depression, defined as a PHQ-9 score <5. For
the majority of participants (82%), the AMI dose was not changed at CDP1.
At the second and third CDPs (weeks 8 and 12), tolerability remained high and remission
rates continued to increase, to 70% and then 87%. By 12 weeks, the median PHQ-9 score
had decreased to 2, with a range of 0-12. Most participants (90% at CDP2, 100% at CDP3)
did not change doses at these CDPs. Final amitriptyline doses at 12 weeks ranged from
25-125 mg daily, with most participants (n=43, 81%) being prescribed 50mg daily.
All participants remained on amitriptyline, the first-line treatment option; no participants
stopped amitriptyline or transitioned to a second-line option over the 12-month study period.
Reductions in depressive symptoms were maintained or improved through 12 months: 90%,
94%, and 100% of respondents achieved full remission at months 4, 8, and 12, respectively,
no serious adverse events were reported, and problematic side effects remained rare.
Intervention fidelity
Overall, fidelity to intervention recommendations by the treating HIV provider was high,
with HIV providers following recommendations in 96% of encounters. At week 4, the
physician's action was congruent with the MBC recommendation in 49/55 cases (89%)
(Table II). Specifically, of 19 participants who had achieved remission, the antidepressant
prescription was maintained for 17 participants (congruent) and decreased for 2 participants
who had self-decreased on their own due to sleep disturbance. Of 30 participants with mild
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ongoing depressive symptoms, the dose was increased or maintained in 29 cases (congruent)
and decreased in 1 case due to tolerable but moderate side effects. Of 6 participants with
ongoing moderate to severe depressive symptoms, the dose was increased in 3 cases
(congruent) and maintained in 3 cases. In one of these cases the participant had been poorly
adherent to the prescribed dose so the decision was to counsel greater adherence to the
original dose. In a second case, even though the participant still had moderate symptoms, the
participant had shown partial response to the original dose so the decision was to maintain
the dose and reassess at week 8. In the third case the participant had shown partial response
and was reporting some tolerable but frequent side effects so the decision was to maintain
the dose and re-assess at week 8.
At CDP2 (week 8), the physician's action was congruent with the MBC recommendation in
49/50 cases (98%). Of 35 participants who had achieved remission, the dose was maintained
in all cases (congruent). Of 12 participants with mild ongoing depressive symptoms, the
dose was increased or maintained in all cases. Of 3 participants with ongoing moderate to
severe depressive symptoms, the dose was increased in 2 cases (congruent) and maintained
in 1 case.
At CDP3 (week 12), the physician's action was congruent with the MBC recommendation in
52/53 cases (98%). Of 46 participants who had achieved remission and 6 participants with
mild ongoing depressive symptoms, the dose was maintained in all cases (congruent). The 1
participant with ongoing moderate to severe depressive symptoms was the same participant
with elevated symptoms whose dose was maintained at week 8. The provider again elected
to maintain the dose, although the dose was eventually increased to 100mg (at 4 months),
after which the participant achieved remission.
Safety and suicidality
Suicidal ideation merits careful monitoring in any study of individuals with major
depression. Some level of passive or active suicidal ideation was endorsed by 62% of
participants at baseline, with 18% endorsing only passive suicidality (thoughts of being
better off dead, but no thoughts about self-harm), 16% endorsing active suicidality assessed
as low-risk, and 27% endorsing active suicidality assessed as moderate risk (Table III). The
proportion of respondents reporting any suicidality dropped to 15% at 4 weeks, 10% at 8
weeks, and 8% at 12 weeks, with active suicidality reported by 4-7% of respondents at each
of these time points. All participants reporting any suicidality were assessed for safety, and
no participant was ever assessed to be an emergent threat to him or herself.
Over the course of the study, no participants showed any clinically concerning signs of
medication toxicity such as delirium or confusion, emerging mania, urinary tract infections,
urinary dysfunction, or poor liver function. Three participants had signs of oral thrush at
week 8, and 4 participants had difficulties with insomnia (one participant reported insomnia
at 2 visits).
Participants were asked to rate the frequency, intensity, and interference of any side effects
they believed were attributable to the amitriptyline. While some side effects were reported,
these were generally mild and posed little interference. The proportion reporting no or only
Pence et al. Page 8






















mild side effects was 72% at 4 weeks, 88% at 8 weeks, and 92% at 12 weeks. In only one
instance did a participant report intolerable side effects prior to physician assessment, and in
this case during the clinical exam the side effects were rated as mild.
Acceptability
Overall, 100% of participants reported being “satisfied” with the Measurement-Based Care
intervention (Table IV). Ninety-six percent said they found MBC to be beneficial to their
health, and 98% said they would recommend MBC to others. Sixty percent said that MBC
added time to their clinic visit, with a median (IQR) estimate of 40 (30-60) minutes, but all
said the extra time was worthwhile. Ninety-four percent and 89% indicated that they were
willing to pay for transportation and medications, respectively, if MBC were to be provided
outside of a research study, and 70% and 68% said they would be able to afford the
necessary transportation and medications.
Discussion
In this single-group pilot study, the adapted Measurement-Based Care intervention
demonstrated high levels of feasibility, safety, acceptability, and preliminary efficacy. In
terms of feasibility, we were successful in training a non-specialist nurse as a Depression
Care Manager to identify major depression and deliver measurement-based medication
treatment recommendations to the managing HIV provider; the provider followed these
treatment recommendation >95% of the time. We were also successful in maintaining
regular supervision of the DCM by a study psychiatrist who reviewed recommendations and
provided ongoing feedback and quality assurance. In terms of safety, few problematic side
effects and no major safety concerns were observed over 3 months of acute-phase treatment.
With respect to acceptability, all participants were satisfied with their MBC experience, with
most expressing willingness to assume the additional costs of medications and clinic visits
for their depression treatment if MBC were part of standard care. Although the study lacked
a control group, efficacy was suggested by the strong and sustained reduction in depressive
symptoms over 12 weeks of treatment, with accompanying reductions in suicidal ideation
and with the vast majority of participants achieving full remission of their depressive
symptoms.
This study represents one of several efforts to develop and test feasible, acceptable, and
effective task-shifting models to enhance mental health treatment capacity in resource-
constrained settings. In the MANAS trial in India, Patel and colleagues observed that a
collaborative stepped-care intervention, administered by trained lay counselors and
complemented with antidepressant medication by the primary care physician and
supervision by a mental health specialist, was effective in initiating recovery from common
mental disorders including depression.(20) Meanwhile, Bolton and colleagues have
demonstrated the efficacy of lay counselor-led interpersonal group therapy to treat
depression in rural Uganda.(21, 22) Petersen et al. additionally illustrated that group-based
interpersonal therapy for depression headed by trained community health workers was
feasible in South Africa.(23) However, to our knowledge this is the first published study of a
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medication management-focused task-shifting model for treatment of depression in a low-
income country.
Both medication-based and counseling-based approaches to depression treatment (including
involvement of traditional and spiritual healers) are likely to be important in efforts to
expand access to mental health treatment in low-resource settings. While a formal cost-
benefit analysis was beyond the scope of this project, the project did demonstrate that a
single DCM without prior specialized training was easily able to manage 55 active patients,
a caseload that would have been challenging had the intervention involved weekly
counseling sessions. With appropriate supervision, depression management could also easily
be integrated into the portfolio of existing clinicians managing other chronic conditions,
such as the clinical officers or nurses who provide front-line HIV care in much of sub-
Saharan Africa.
A primary limitation of this pilot study was the single-group design. In the absence of a
randomized design, we cannot rule out the possibility that participants would have improved
without treatment or simply with increased attention, rather than because of the MBC
intervention specifically. However, nearly all participants reported having had past
depressive episodes, with half reporting three or more prior episodes; such recurrent
depression would be unlikely to resolve quickly on its own,(24-26) and screening and
supportive care in the absence of formal evidence-based depression treatment generally does
not have a strong or sustained effect on depressive symptoms as observed here. (27) In
addition, the high prevalence of suicidal ideation, especially active ideation, at enrollment
and the subsequent decline support the likelihood of a treatment effect.
An additional limitation of the study was the limited availability of alternative
antidepressants and treatment options. Amitriptyline, a tricyclic antidepressant (TCA), was
the only antidepressant available on the government essential drug list. Amitriptyline and
other TCAs have potentially problematic toxicities including sedation and anticholinergic
effects. In this small pilot study no one experienced problematic side effects from
amitriptyline and most participants exhibited a strong response to treatment, but the
identification of alternative treatment options would be important to consider in larger-scale
implementation. Although the most concerning interactions of TCAs are with the protease
inhibitor class of antiretrovirals,(18, 19) which are uncommonly prescribed in Cameroon,
the addition of an antidepressant from the more benign SSRI class would likely be
beneficial.
Although no medication-related safety concerns were observed in this study, the small size
of this pilot may have prevented the identification of uncommon but important side effects
that are possible with TCAs, including anticholinergic delirium, confusion, seizure, and
cardiac arrhythmias.(17) Careful monitoring of side effects would be warranted in further
studies, especially if such studies continue to rely on TCAs.
In summary, in this study we successfully adapted Measurement-Based Care for
implementation with HIV patients in Bamenda, Cameroon, and demonstrated its feasibility,
safety, acceptability, and preliminary efficacy in a small, single-group pilot study. Task-
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shifting models, particularly models such as Measurement-Based Care that equip non-
specialist medical providers to effectively prescribe and monitor antidepressants, hold great
potential to expand the currently extremely low capacity for mental health treatment that
characterizes most low-income countries. Additional research should focus on whether
evidence-based depression treatment will improve HIV-related outcomes such as retention
in care, medication adherence, and virologic suppression in such settings in order to define
the full potential benefit of investing in mental health treatment for HIV-infected
individuals.
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General schedule of Measurement-Based Care patient contacts to monitor and adjust acute
phase antidepressant treatment.
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Critical Decision Point decision tree for antidepressant treatment adjustment after
assessment of depressive severity and tolerability of side effects.
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Table I
Description of sample
Characteristic n (%) or median (IQR)
Total 55
Gender
    Male 11 (20%)
    Female 44 (80%)
Age 40 (33-44)
Marital status
    Married or partnered 8 (15%)
    Never married 18 (33%)
    Widowed or divorced 29 (53%)
Educational attainment
    None 1 (2%)
    Primary 31 (56%)
    Secondary 17 (31%)
    Tertiary 6 (11%)
Daily expenditures (USD) 4.55 (2.80-7.31)
CD4 (cells/mm3) 454 (242-612)
HIV RNA viral load (copies/mL) 12,304 (7,308-21,555)
    HIV RNA viral load <400 0 (0%)
Prior depressive episodes
    None 2 (4%)
    1 6 (11%)
    2 19 (35%)
    3 or more 27 (49%)
Ever treated for depression 1 (2%)
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Table IV
Acceptability of intervention
Indicator n (%) or median (IQR)
Satisfied overall with MBC 53 (100%)
Find MBC beneficial to health 51 (96%)
Would recommend MBC to others 52 (98%)
MBC makes clinic visits longer 32 (60%)
    Extra time due to MBC, minutes 40 (30-60)
    Additional time worthwhile 32 (100%)
Additional visits for MBC 32 (60%)
    Number of additional visits 2 (2-3)
    Additional visits worthwhile 32 (100%)
Time away from duties due to MBC, mins 40 (30-90)
Physical discomfort from MBC 3 (6%)
    Severity - mild 2 (100%)
    Discomfort acceptable 2 (100%)
Emotional discomfort from MBC 1 (2%)
    Severity – mild
NA
*
    Discomfort acceptable
NA
*
Cost of transport to/from clinic, US$ $0.80 ($0.60-$1.60)
Willing to pay for transport 50 (94%)
Able to pay for transport 37 (70%)
Willing to pay for meds 47 (89%)
Able to pay for meds 36 (68%)
Time to travel to clinic, minutes 35 (20-60)
*
The 1 participant identifying emotional discomfort did not rate the severity.
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